Simon Hudson, Bob Gray, Jeremy Cook. HFL Sport Science, LGC Health Sciences, Fordham, UK

Total Page:16

File Type:pdf, Size:1020Kb

Simon Hudson, Bob Gray, Jeremy Cook. HFL Sport Science, LGC Health Sciences, Fordham, UK Occupational Drug Screening using High Resolution Accurate Mass LCMS Simon Hudson, Bob Gray, Jeremy Cook. HFL Sport Science, LGC Health Sciences, Fordham, UK Overview Methods Conclusions Current available information demonstrates the rapid growth in the availability Historically, workplace drug testing has been based on immunoassay technology A batch of samples for analysis for ‘designer’ drugs was submitted to LGC Health Four samples were positive for pentedrone using the enhanced test. Pentedrone and use of substances collectively known as ‘legal highs’. This in turn presents a operating on large clinical analysers. The advantages to this have been low cost, Sciences for ‘workplace drug testing’. The routine workplace analysis using alone, as in Sample13 did not trigger a positive in the conventional test. Likewise, challenge to the delivery of effective meaningfull workplace drug tests. high throughput and adequate performance in terms of drug coverage and Olympus AU2700 clinical analysers with standard test kits was performed on each 4-methylmethcathinone, fluoroephedrine, benzylpiperazine, trifluoro- The comparison of traditional immunoassay/clinical analyser based workplace sensitivity. The main disadvantages have been the availability of tests and, more sample. methylphenylpiperazine and methylhexanamine did not generate a positive result drug testing with a broad coverage LCMS approach demonstrates clearly that the recently, the ability to keep up with the emergence of new ‘legal’ highs. The same samples were also submitted for the ‘Enhanced Workplace Test’ as on the clinical analyser. traditional approach is severely limited in terms of drug coverage. The use of high 60 follows. 4-methylmethcathinone was detected in the conventional workplace test for Beta glucuronidase hydrolysed urine samples were prepared for analysis using a resolution accurate mass LCMS delivers several performance advantages:- 50 A recent phenomenon is that of syn- sample 12. A positive response was seen on the amphetamine immunoassay. multi eluate sold phase extraction methodology to prepare both an acid/neutral 40 thetic cannabinoids, otherwise known The GCMS follow up to the immunoassay detected the presence of as ‘Spice’. Reagents are available for and a basic fraction. The extracts were then combined, with a portion of the acid/ Broad Analyte Coverage—demonstrated by the analysis of city centre pooled 30 New Psychoactive 4-methylmethcathinone. This however was anomalous with the fact that a Substances Reported in urine samples. Europe - source clinical analyser based screening but neutral fraction being retained in case of any requirement for anabolic steroid 20 EMCDDA 4-methylmethcatrhinone standard at high concentration does not give a response the coverage of the 70 or more testing. Rapid Response—it is very easy to add new analytes to data processing 10 on the amphetamine test. In addition, none of the other 4-methylmethcathinone potential compounds is very limited. The combined extracts were analysed using full scan HRAM LCMS on a Thermo databases to extend drug coverage. No modification to instrument methodology 0 samples were positive on the clinical analyser. LTQ Orbitrap operating at a resolution of 30,000 is required. 2008 2009 2010 2011 The cause of the initial positive on the amphetamine test is therefore unknown and FWHM in positive ion electrospray mode. The High Selectivity—first pass identification of drug compound is usually possible. the finding of 4-methylmethcathinone in sample 12 is by pure chance. chromatography was performed on a ballistic Reduced False Positives—due to high selectivity of primary HRAM LCMS The current availability of robust and sensitive high resolution accurate mass acetic acid/acetonitrile gradient using a Water screen. Reduction in wasted confirmation work. (HRAM) LCMS instrumentation has presented an opportunity to deliver a truly fit City Centre Samples for purpose workplace test that can cover a wide range of analytes and that is Atlantis T3 column. Starting conditions were Reduced False Negatives—increased coverage hence less chance of missing 100% aqueous ending with 98% organic in a 5 The analysis of the samples from the city centre urinals identified a large number ‘positive’ samples easy to add new analytes to. The application of this technology to deliver an of ‘normal’ prescription or over the counter drugs. In addition, most samples ‘Enhanced’ workplace test is described. minute analysis. High Sensitivity—method capability into the low ppb and high ppt ranges. contained large amounts—in the 100’s ng to low µg/ml range— of ketamine, The resulting data file was processed using Thermo ExactFinder software against a benzoylecgonine, amphetamine and MDMA. Nearly 150 drugs were detected, Possible drawbacks to the use of this approach include the cost and the need for database of over 1600 analytes using accurate either as parent compound or metabolite. high throughput. mass, retention time, isotopic profiling and in source generated qualifier fragment ions as determinands. Other findings of ‘legal high’ type compounds to date include:- Introduction The same protocol was also employed on a study of drug use in the night time References economy of central London. Temporary urinals (pissoirs) are placed in strategic cathinone variants including:cathinone, methcathinone, 4-methylmethcathinone, The use of high resolution accurate mass spectrometry for rapid throughput, multi Standard urine-based occupational drug screening is a two-stage process, involv- positions in city centres to provide toilet facilities for late night visitors, typically on 4-methylethcathinone and beta ethyl methcathinone (pentedrone) -drug screening, S. Hudson, S. Maynard and S. Timbers, Proceedings of the 18th In- a Saturday night. These are emptied on a Sunday morning and at this point a ing initial immunoassay screening to identify possible positive samples followed by piperazines including 1,4 trifluoromethylphenylpiperazine, benzylpiperazine and ternational Conference of Racing Analysts and Veterinarians, New Zealand 2010 more detailed and targeted gas or liquid chromatography coupled with mass sample is retained for analysis methylphenylpiperazine Analysis of anonymous pooled urine from portable urinals in central London con- firms the significant use of novel psychoactive substances, Archer JR, Dargan PI, spectrometry to confirm and quantify the materials present. This combination other analytes including 4-fluorephedrine 6-APB, methoxetamine and Hudson S, Wood DM., QJM. 2013 Feb;106(2):147-52. doi: 10.1093/qjmed/hcs219. Epub provides a cost-effective means of conducting large scale testing, but means that methiopropamine. Results 2012 Nov 22 materials which do not trigger the initial immunoassay will not be detected. 1,4 methoxyphenylpiperazine chlordiazepoxide gabapentin morphine propranolol Taking the Pissoir – a novel and reliable way of knowing what drugs are being Workplace Tests 4 methylethcathinone chloroquine guaifenesin Nandrolone pyrimethamine Current urine-based workplace drug testing schemes cover a relatively limited used in nightclubs, Archer, J. R. H,, Dargan, P. I., Hudson, S., Davies, S., range of illicit substances which can be broken down into the following groups :- A comparison of results from the ‘Conventional’ and ‘Enhanced’ workplace test for 4-ethylmethcathinone chlorpheniramine HMMA naproxen quetiapine 4-fluoroephedrine Chlorthalidone hordenine nefopam quinine Puchnarewicz, M., Kicman, A. T., Ramsey, J., Measham, F., Wood, M., Johnston, A., Opiates this batch of samples shows a large increase in findings in the LCMS analysis. 4-methylmethcathinone cimetidine hydrochlorthiazide nevirapine ranitidine Wood, D. M. Journal of Substance Use. Posted online on May 6, 2013. 5/6-APB citalopram Ibuprofen nicotine risperidone Amphetamines Samples found positive for cocaine on the conventional test were also positive for (doi:10.3109/14659891.2012.740139) cocaine (as benzoylecgonine) on the enhanced screen. Other metabolites ambroxol clenbuterol isometheptene niflumic acid salbutamol Benzodiazepines amisulpiride clobazam ketamine nordazepam sertaline Cannabis (hydroxy cocaine, ecgonine methyl ester, ecgonine ethyl ester) were also identified amitriptylline clomipramine Ketoprofen nortriptyline sildenafil amphetamine clozapine lamotrigine noscapine sotalol Cocaine by LCMS. ampyrone codeine lansoprazole Olanzapine Stanozolol Other targeted analytes depending on availability of kits arecoline cotinine Lidocaine omeprazole sulpiride atenolol cyclobenzaprine MDA opipramol tamoxifen Conventional Work- Sample No. Enhanced Workplace Test benzocaine DEET MDMA oripavine temazepam There is limited coverage for place Test benzoylecgonine desloratidine Meclofenamic acid orphenadrine tetracycline benzydamine dextromethorphan mefenamic acid oxazepam tetramisole Sample 1 4 methylmethcathinone/fluorephedrine many of the designer drugs and bisoprolol dextrorphan methadone oxprenolol theobromine Sample 2 negative bromhexine Diazepam methamphetamine oxycodone theophylline so called ‘legal highs’ that are now Sample 3 Cocaine pentedrone/benzoylecgonine buprenorphine diclofenac methcathinone oxytetracycline tramadol widely abused, and due to the Sample 4 Cocaine pentedrone/benzoylecgonine buprenorphine-nor dihydrocodeine methiopropamine papaverine Trazodone caffeine dihydromorphine methoxetamine paracetamol trenbolone 4 methylmethcathinone/fluorephedrine/ nature of the testing, conventional Sample 5
Recommended publications
  • International Collaborative Exercises (Ice)
    INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP) INTERNATIONAL COLLABORATIVE EXERCISES (ICE) Summary Report BIOLOGICAL SPECIMENS 2013/2 INTERNATIONAL QUALITY ASSURANCE PROGRAMME (IQAP) INTERNATIONAL COLLABORATIVE EXERCISES (ICE) Table of contents Introduction Page 3 Comments from the International Panel of Forensic Experts Page 3 Codes and Abbreviations Page 4 Sample 1 Analysis Page 5 Identified substances Page 5 Statement of findings Page 6 Identification methods Page 10 Summary Page 12 Z-Scores Page 13 Sample 2 Analysis Page 15 Identified substances Page 15 Statement of findings Page 16 Identification methods Page 20 Summary Page 22 Z-Scores Page 23 Sample 3 Analysis Page 25 Identified substances Page 25 Statement of findings Page 27 Identification methods Page 31 Summary Page 33 Z-Scores Page 34 Sample 4 Analysis Page 36 Identified substances Page 36 Statement of findings Page 38 Identification methods Page 42 Summary Page 44 Test Samples Information Samples Comments on samples Sample 1 To prepare BS-1, urine was spiked with 4-Bromo-2,5-dimethoxyphenethylamine (2C-B) (1590 ng base/ml), as an ethanolic solution. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 2 To prepare BS-2, urine was spiked with Gammahydroxybutyrate (GHB) (14360 ng base/ml), as an aqueous solution. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 3 To prepare BS-3, urine was spiked with Amfetamine sulphate (1570ng/ml, 1150 ng base/ml) and Metamfetamine hydrochloride (4290 ng/ml, 3450 ng base/ml) as aqueous solutions. The spiked urine was dispensed in 50ml aliquots and lyophilised Sample 4 BS-4 was a blank test sample containing no substances in the ICE menu Samples Substances Concentrations Comments on substances Sample 1 4-Bromo-2,5-dimethoxyphenethylamine (2C- 1590 ng/ml B) Sample 2 gamma-Hydroxybutyric acid (GHB) 14360 ng/ml Sample 3 Metamfetamine 3450 ng/ml Amfetamine 1150 ng/ml Sample 4 [blank sample] This report contains the data received from laboratories participating in the current exercise.
    [Show full text]
  • WHO Expert Committee on Drug Dependence Thirty-Eighth Report
    WHO Expert Committee on Drug Dependence Thirty-eighth report This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization iii Contents WHO Expert Committee on Drug Dependence vi Abbreviations ix Introduction 1 1. Briefings from International Organizations on their work on the public health element of the world drug problem 4 1.1 Update from the International Narcotics Control Board 4 1.2 Update from the United Nations Office on Drugs and Crime 5 1.3 Update from the Department of Essential Medicines and Health Products, WHO 7 1.4 Update from the Department of Mental Health and Substance Abuse, WHO 9 1.5 Update from the Department of HIV/AIDS, WHO 9 2. Principles for prioritizing and assessing substances as part of ECDD work 11 3. Update from the 1st Informal Working Group of the ECDD 12 4. Follow-up on recommendations made by the ECDD at its thirty-seventh meeting 13 5. Critical review of psychoactive substances 14 5.1 U- 47700 15 5.2 Butyrfentanyl (Butyrylfentanyl) 17 5.3 4-Methylethcathinone (4-MEC) 18 5.4 3-Methylmethcathinone (3-methyl-N-methylcathinone; 3-MMC) 21 iv 5.5 Ethylone (3,4-metheylenedioxy-N-ethylcathinone; bk-MDEA; MEDEC) 23 5.6 Pentedrone (α-Methylaminovalerophenone) 24 5.7 Ethylphenidate (EPH) 26 5.8 Methiopropamine (MPA) 28 5.9 MDMB-CHMICA 30 5.10 5F-APINACA (5F-AKB-48) 32 5.11 JWH-073 34 5.12 XLR-11 36 6. Updates 37 6.1 Cannabis and cannabis resin 37 7.
    [Show full text]
  • Supporting Information a Analysed Substances
    Electronic Supplementary Material (ESI) for Analyst. This journal is © The Royal Society of Chemistry 2020 List of contents: Tab. A1 Detailed list and classification of analysed substances. Tab. A2 List of selected MS/MS parameters for the analytes. Tab. A1 Detailed list and classification of analysed substances. drug of therapeutic doping agent analytical standard substance abuse drug (WADA class)* supplier (+\-)-amphetamine ✓ ✓ S6 stimulants LGC (+\-)-methamphetamine ✓ S6 stimulants LGC (+\-)-3,4-methylenedioxymethamphetamine (MDMA) ✓ S6 stimulants LGC methylhexanamine (4-methylhexan-2-amine, DMAA) S6 stimulants Sigma cocaine ✓ ✓ S6 stimulants LGC methylphenidate ✓ ✓ S6 stimulants LGC nikethamide (N,N-diethylnicotinamide) ✓ S6 stimulants Aldrich strychnine S6 stimulants Sigma (-)-Δ9-tetrahydrocannabinol (THC) ✓ ✓ S8 cannabinoids LGC (-)-11-nor-9-carboxy-Δ9-tetrahydrocannabinol (THC-COOH) S8 cannabinoids LGC morphine ✓ ✓ S7 narcotics LGC heroin (diacetylmorphine) ✓ ✓ S7 narcotics LGC hydrocodone ✓ ✓ Cerillant® oxycodone ✓ ✓ S7 narcotics LGC (+\-)-methadone ✓ ✓ S7 narcotics Cerillant® buprenorphine ✓ ✓ S7 narcotics Cerillant® fentanyl ✓ ✓ S7 narcotics LGC ketamine ✓ ✓ LGC phencyclidine (PCP) ✓ S0 non-approved substances LGC lysergic acid diethylamide (LSD) ✓ S0 non-approved substances LGC psilocybin ✓ S0 non-approved substances Cerillant® alprazolam ✓ ✓ LGC clonazepam ✓ ✓ Cerillant® flunitrazepam ✓ ✓ LGC zolpidem ✓ ✓ LGC VETRANAL™ boldenone (Δ1-testosterone / 1-dehydrotestosterone) ✓ S1 anabolic agents (Sigma-Aldrich)
    [Show full text]
  • Structure-Cytotoxicity Relationship Profile of 13 Synthetic Cathinones In
    Neurotoxicology 75 (2019) 158–173 Contents lists available at ScienceDirect Neurotoxicology journal homepage: www.elsevier.com/locate/neuro Structure-cytotoxicity relationship profile of 13 synthetic cathinones in differentiated human SH-SY5Y neuronal cells T ⁎ Jorge Soaresa, , Vera Marisa Costaa, Helena Gasparb,c, Susana Santosd,e, Maria de Lourdes Bastosa, ⁎ Félix Carvalhoa, João Paulo Capelaa,f, a UCIBIO, REQUIMTE (Rede de Química e Tecnologia), Laboratório de Toxicologia, Departamento de Ciências Biológicas, Faculdade de Farmácia, Universidade do Porto, Portugal b BioISI – Instituto de Biossistemas e Ciências Integrativas, Faculdade de Ciências, Universidade de Lisboa, Portugal c MARE - Centro de Ciências do Mar e do Ambiente, Escola Superior de Turismo e Tecnologia do Mar, Instituto Politécnico de Leiria, Portugal d Centro de Química e Bioquímica (CQB), Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade de Lisboa, Portugal e Centro de Química Estrutural, Faculdade de Ciências, Universidade de Lisboa, Portugal f FP-ENAS (Unidade de Investigação UFP em Energia, Ambiente e Saúde), CEBIMED (Centro de Estudos em Biomedicina), Faculdade de Ciências da Saúde, Universidade Fernando Pessoa, Portugal ARTICLE INFO ABSTRACT Keywords: Synthetic cathinones also known as β-keto amphetamines are a new group of recreational designer drugs. We Synthetic cathinones aimed to evaluate the cytotoxic potential of thirteen cathinones lacking the methylenedioxy ring and establish a Classical amphetamines putative structure-toxicity profile using differentiated SH-SY5Y cells, as well as to compare their toxicity to that Cytotoxicity of amphetamine (AMPH) and methamphetamine (METH). Cytotoxicity assays [mitochondrial 3-(4,5-dimethyl-2- SH-SY5Y cells thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction and lysosomal neutral red (NR) uptake] per- Structure-toxicity relationship formed after a 24-h or a 48-h exposure revealed for all tested drugs a concentration-dependent toxicity.
    [Show full text]
  • Booklet 4 Stimulants Preface
    4 STIMULANTS 4 STIMULANTS 2019 2019 © United Nations, June 2019. All rights reserved worldwide. ISBN: 978-92-1-148314-7 eISBN: 978-92-1-004174-4 United Nations publication, Sales No. E.19.XI.8 This publication may be reproduced in whole or in part and in any form for educational or non-profit purposes without special permission from the copyright holder, provided acknowledgement of the source is made. The United Nations Office on Drugs and Crime (UNODC) would appreciate receiving a copy of any publication that uses this publication as a source. Suggested citation: World Drug Report 2019 (United Nations publication, Sales No. E.19.XI.8). No use of this publication may be made for resale or any other commercial purpose whatsoever without prior permission in writing from UNODC. Applications for such permission, with a statement of purpose and intent of the reproduction, should be addressed to the Research and Trend Analysis Branch of UNODC. DISCLAIMER The content of this publication does not necessarily reflect the views or policies of UNODC or contributory organizations, nor does it imply any endorsement. Comments on the report are welcome and can be sent to: Division for Policy Analysis and Public Affairs United Nations Office on Drugs and Crime PO Box 500 1400 Vienna Austria Tel: (+43) 1 26060 0 Fax: (+43) 1 26060 5827 E-mail: [email protected] Website: www.unodc.org/wdr2019 PREFACE The findings of this year’s World Drug Report fill in same time clamping down on organized crime and and further complicate the global picture of drug trafficking.
    [Show full text]
  • Toxicology Report Division of Toxicology Daniel D
    Franklin County Forensic Science Center Office of the Coroner Anahi M. Ortiz, M.D. 2090 Frank Road Columbus, Ohio 43223 Toxicology Report Division of Toxicology Daniel D. Baker, Chief Toxicologist Casey Goodson Case # LAB-20-5315 Date report completed: January 28, 2021 A systematic toxicological analysis has been performed and the following agents were detected. Postmortem Blood: Gray Top Thoracic ELISA Screen Acetaminophen Not Detected ELISA Screen Barbiturates Not Detected ELISA Screen Benzodiazepines Not Detected ELISA Screen Benzoylecgonine Not Detected ELISA Screen Buprenorphine Not Detected ELISA Screen Cannabinoids See Confirmation ELISA Screen Fentanyl Not Detected ELISA Screen Methamphetamine Not Detected ELISA Screen Naltrexone/Naloxone Not Detected ELISA Screen Opiates Not Detected ELISA Screen Oxycodone/Oxymorphone Not Detected ELISA Screen Salicylates Not Detected ELISA Screen Tricyclics Not Detected Page 1 of 4 Casey Goodson Case # LAB-20-5315 GC/FID Ethanol Not Detected GC/MS Acidic/Neutral Drugs None Detected GC/MS Nicotine Positive GC/MS Cotinine Positive Reference Lab Delta-9-THC 13 ng/mL Reference Lab 11-Hydroxy-Delta-9-THC 1.2 ng/mL Reference Lab 11-Nor-9-Carboxy-Delta-9-THC 15 ng/mL Postmortem Urine: Gray Top Urine GC/MS Cotinine Positive This report has been verified as accurate and complete by ______________________________________ Daniel D. Baker, M.S., F-ABFT Cannabinoid quantitations in blood were performed by NMS Labs, Horsham, PA. Page 2 of 4 Casey Goodson Case # LAB-20-5315 Postmortem Toxicology Scope of Analysis Franklin County Coroner’s Office Division of Toxicology Enzyme Linked Immunosorbant Assay (ELISA) Blood Screen: Qualitative Presumptive Compounds/Classes: Acetaminophen (cut-off 10 µg/mL), Benzodiazepines (cut-off 20 ng/mL), Benzoylecgonine (cut-off 50 ng/mL), Cannabinoids (cut-off 40 ng/mL), Fentanyl (cut-off 1 ng/mL), Methamphetamine/MDMA (cut-off 50 ng/mL), Opiates (cut-off 40 ng/mL), Oxycodone/Oxymorphone (cut-off 40 ng/mL), Salicylates (50 µg/mL).
    [Show full text]
  • 4F-Pentedrone
    NMS Labs 2300 Stratford Ave Willow Grove, PA 19090 4F-Pentedrone Sample Type: Seized Material Latest Revision: December 3, 2019 Date Received: August 16, 2019 Date of Report: December 3, 2019 1. GENERAL INFORMATION IUPAC Name: 1-(4-fluorophenyl)-2-(methylamino)pentan-1-one InChI String: InChI=1S/C12H16FNO/c1-3-4-11(14-2)12(15)9-5-7-10(13)8-6- 9/h5-8,11,14H,3-4H2,1-2H3 CFR: Not Scheduled (12/2019) CAS# Not Available Synonyms: 4-Fluoro Pentedrone, 4-Fluoro-α-Methylamino-Valerophenone, 4-FPD Source: Department of Homeland Security Appearance: Tan Solid Material Important Note: All identifications were made based on evaluation of analytical data (GC-MS and LC- QTOF-MS) in comparison to analysis of acquired reference material. Prepared By: Alex J. Krotulski, PhD; Melissa F. Fogarty, MSFS, D-ABFT-FT; and Barry K. Logan, PhD, F-ABFT 2. CHEMICAL AND PHYSICAL DATA 2.1 CHEMICAL DATA Chemical Molecular Molecular Ion Exact Mass Form Formula Weight [M+] [M+H]+ Base C12H16FNO 209.3 209 210.1289 3. BRIEF DESCRIPTION 4F-Pentedrone is classified as a novel stimulant and substituted cathinone. Substituted cathinones are modified based on the structure of cathinone, an alkaloid found in the Khat plant. Novel stimulants have been reported to cause stimulant-like effects, similar to amphetamines. Novel stimulants have also caused adverse events, including deaths, as described in the literature. Structurally similar compounds include pentedrone, hexedrone, and N-ethyl hexedrone. Pentedrone is a Schedule I substance in the United States while 4F-pentedrone is not explicitly scheduled.
    [Show full text]
  • AGENDA Friday, September 9, 2016 7:00 A.M
    Needham Board of Health AGENDA Friday, September 9, 2016 7:00 a.m. – 9:00 a.m. Charles River Room – Public Services Administration Building 500 Dedham Avenue, Needham MA 02492 • 7:00 to 7:05 - Welcome & Review of Minutes (July 29 & August 29) • 7:05 to 7:30 - Director and Staff Reports (July & August) • 7:30 to 7:45 - Discussion about Proposed Plastic Bag Ban Christopher Thomas, Needham Resident • 7:45 to 7:50 - Off-Street Drainage Bond Discussion & Vote • 7:50 to 8:00 - Update on Wingate Pool Variance Application * * * * * * * * * * * * * Board of Health Public Hearing • 8:00 to 8:40 - Hearing for Proposed New or Amended BOH Regulations o Body Art o Synthetic Marijuana o Drug Paraphernalia • 8:40 to 8:50 - Board Discussion of Policy Positions • Other Items (Healthy Aging, Water Quality) • Next Meeting Scheduled for Friday October 14, 2016 • Adjournment (Please note that all times are approximate) 1471 Highland Avenue, Needham, MA 02492 781-455-7500 ext 511 (tel); 781-455-0892 (fax) E-mail: [email protected] Web: www.needhamma.gov/health NEEDHAM BOARD OF HEALTH July 29, 2016 MEETING MINUTES PRESENT: Edward V. Cosgrove, PhD, Chair, Jane Fogg, Vice-Chair, M.D., and Stephen Epstein, M.D STAFF: Timothy McDonald, Director, Donna Carmichael, Catherine Delano, Maryanne Dinell, Tara Gurge GUEST: Kevin Mulkern, Aquaknot Pools, Inc., Keith Mulkern, Aquaknot Pools, Inc., David Friedman, Wingate, Paul Humphreys, Michael Tomasello, Callahan, Inc. CONVENE: 7:00 a.m. – Public Services Administration Building (PSAB), 500 Dedham Avenue, Needham MA 02492 DISCUSSION: Call To Order – 7:06 a.m. – Dr. Cosgrove, Chairman APPROVE MINUTES: Upon motion duly made and seconded, the minutes of the BOH meeting of June 17, 2016 were approved as submitted.
    [Show full text]
  • Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected]
    Florida International University FIU Digital Commons FIU Electronic Theses and Dissertations University Graduate School 4-25-2018 Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances Joshua Zolton Seither [email protected] DOI: 10.25148/etd.FIDC006565 Follow this and additional works at: https://digitalcommons.fiu.edu/etd Part of the Chemistry Commons Recommended Citation Seither, Joshua Zolton, "Application of High Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances" (2018). FIU Electronic Theses and Dissertations. 3823. https://digitalcommons.fiu.edu/etd/3823 This work is brought to you for free and open access by the University Graduate School at FIU Digital Commons. It has been accepted for inclusion in FIU Electronic Theses and Dissertations by an authorized administrator of FIU Digital Commons. For more information, please contact [email protected]. FLORIDA INTERNATIONAL UNIVERSITY Miami, Florida APPLICATION OF HIGH RESOLUTION MASS SPECTROMETRY FOR THE SCREENING AND CONFIRMATION OF NOVEL PSYCHOACTIVE SUBSTANCES A dissertation submitted in partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY in CHEMISTRY by Joshua Zolton Seither 2018 To: Dean Michael R. Heithaus College of Arts, Sciences and Education This dissertation, written by Joshua Zolton Seither, and entitled Application of High- Resolution Mass Spectrometry for the Screening and Confirmation of Novel Psychoactive Substances, having been approved in respect to style and intellectual content, is referred to you for judgment. We have read this dissertation and recommend that it be approved. _______________________________________ Piero Gardinali _______________________________________ Bruce McCord _______________________________________ DeEtta Mills _______________________________________ Stanislaw Wnuk _______________________________________ Anthony DeCaprio, Major Professor Date of Defense: April 25, 2018 The dissertation of Joshua Zolton Seither is approved.
    [Show full text]
  • Written Witness Statement for U.S. Sentencing Commission's Public
    STATEMENT OF TERRENCE L. BOOS, PH.D. SECTION CHIEF DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION and CASSANDRA PRIOLEAU, PH.D. DRUG SCIENCE SPECIALIST DRUG AND CHEMICAL EVALUATION SECTION DIVERSION CONTROL DIVISION DRUG ENFORCEMENT ADMINISTRATION - - - BEFORE THE UNITED STATES SENTENCING COMMISSION - - - HEARING ON SENTENCING POLICY FOR SYNTHETIC DRUGS - - - OCTOBER 4, 2017 WASHINGTON, D.C. 1 Introduction New Psychoactive Substances (NPS) are substances trafficked as alternatives to well- studied controlled substances of abuse. NPS have demonstrated adverse health effects such as paranoia, psychosis, and seizures to name a few. Cathinones, cannabinoids, and fentanyl-related substances are the most common NPS drug classes encountered on the illicit drug market, all with negative consequences for the user to include serious injury and death. Our early experience saw substances being introduced from past research efforts in an attempt to evade controls. This has evolved to NPS manufacturers structurally altering substances at a rapid pace with unknown outcomes to targeting specific user populations. These substances represent an unprecedented level of diversity and consequences. Due to clandestine manufacture and unscrupulous trafficking, the user is at great risk. A misconception exists that these substances carry a lower risk of harm In reality, published reports from law enforcement, emergency room physicians and scientists, accompanied with autopsies from medical examiners, have clearly demonstrated the harmful and potentially deadly consequences of using synthetic cathinones. These substances are introduced in an attempt to circumvent drug controls and the recent flood of NPS remains a challenge for law enforcement and public health. The United Nations Office on Drugs and Crime reported over 700 NPS encountered.1 The manufacturers and traffickers make minor changes in the chemical structure of known substances of abuse and maintain the pharmacological effect.
    [Show full text]
  • Federal Register/Vol. 82, No. 7/Wednesday, January 11, 2017
    3326 Federal Register / Vol. 82, No. 7 / Wednesday, January 11, 2017 / Notices is responsible for oversight and DEPARTMENT OF HEALTH AND such as medical information, your or implementation of the MSP provisions HUMAN SERVICES anyone else’s Social Security number, or as part of its overall authority for the confidential business information, such Medicare program. The CMS Food and Drug Administration as a manufacturing process. Please note accomplishes this through a [Docket No. FDA–2016–N–4619] that if you include your name, contact combination of direct CMS action and information, or other information that work by CMS’ contractors. The CMS International Drug Scheduling; identifies you in the body of your efforts include policy and operational Convention on Psychotropic comments, that information will be guidelines, including regulations (as Substances; Single Convention on posted on https://www.regulations.gov. • If you want to submit a comment necessary), as well as oversight over Narcotic Drugs; World Health with confidential information that you contractor MSP responsibilities. As a Organization; Scheduling Recommendations; 4- do not wish to be made available to the result of litigation in the mid-1990’s, public, submit the comment as a certain GHP insurers were mandated to Methylethcathinone and Nine Other Substances; Request for Comments written/paper submission and in the report coverage information for a manner detailed (see ‘‘Written/Paper number of years. Subsequent to this AGENCY: Food and Drug Administration, Submissions’’ and ‘‘Instructions’’). litigation related mandatory reporting, HHS. Written/Paper Submissions CMS instituted a Voluntary Data ACTION: Notice. Sharing Agreement (VDSA) effort which Submit written/paper submissions as expanded the scope of the GHP SUMMARY: The Food and Drug follows: • participants and added some NGHP Administration (FDA) is providing Mail/Hand delivery/Courier (for participants.
    [Show full text]
  • January 2020 Sanctions List Full
    GLOBAL LIST OF INELIGIBLE PERSONS Period of Date of Discipline Date of Ineligibility Lifetime Infraction Name Nationality Role Sex Discipline 2 Sanction Disqualification ADRV Rules ADRV Notes Description Birth 1 Infraction until Ban? Type of results ABAKUMOVA, Maria 15/01/1986 RUS athlete F Javelin Throws 21/08/2008 4 years 17/05/2020 From 21.08.08 to No Doping Presence,Use Dehydrochloromethyltestos In competition test, XXIX Olympic ineligibility 20.08.12 terone games, Beijing, CHN ABDOSH, Ali 25/08/1987 ETH athlete M Long Distance 24/12/2017 4 years 04/02/2022 Since 24-12-2017 No Doping Presence,Use Salbutamol In competition test, 2017 Baoneng (3000m+) ineligibility Guangzhou Huangpu Marathon , ACHERKI, Mounir 09/02/1981 FRA athlete M 1500m Middle Distance 01/01/2014 4 years 15/04/2021 Since 01-01-2014 No Doping Use,Possessio Use or Attempted Use by an IAAF Rule 32.2(b) Use of a prohibited (800m-1500m) ineligibility n Athlete of a Prohibited substance ADAMCHUK, Mariya 29/05/2000 UKR athlete F Long Jump Jumps 03/06/2018 4 years 16/08/2022 Since 03.06.18 No Doping Presence,Use Benzoylecgonine In competition test, XXI Cross Citta ineligibility di Novi Ligure, Novi Ligure, ITA ADEKOYA, Kemi 16/01/1993 BRN athlete F 400m Sprints (400m or 24/08/2018 4 years 25/11/2022 Since 24.08.18 No Doping Presence,Use Stanozolol Out-of-competition test, Jakarta, IDN Hurdles less) ineligibility ADELOYE, Tosin 07/02/1996 NGR athlete F 400m Sprints (400m or 24/07/2015 8 years 23/07/2023 Since 24-07-2015 No Doping Presence,Use Exogenous Steroids In competition
    [Show full text]